Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma

Katie S. Nason, Benjamin O. Anderson, David R. Byrd, Lisa K. Dunnwald, Janet F. Eary, David A. Mankoff, Robert B Livingston, Rodney A. Schmidt, Kim D. Jewell, Raymond S. Yeung, Roger E. Moe

Research output: Contribution to journalArticle

252 Citations (Scopus)

Abstract

BACKGROUND. Sentinel lymph node dissection (SLND) has been a promising new technique in breast carcinoma staging, but could be unreliable in certain patient subsets. The current study assessed whether age, preoperative chemotherapy, tumor size, and/or previous excisional biopsy influenced the identification of sentinel nodes (SLNs) or the reliability of a node-negative SLND in predicting a node negative axilla. METHODS. Eighty-two patients who had clinically negative axillae underwent SLND followed by Level I/II axillary lymph node dissection (ALND). SLNDs were performed using both technetium-99m (Tc-99m) labeled colloid and isosulfan blue dye. SLNs were analyzed by hematoxlyin and eosin and immunocytochemical techniques. RESULTS. SLNs were successfully identified in 80% of patients. Mapping success was decreased among postmenopausal women but was not influenced by preoperative chemotherapy, large tumor size, or previous excisional biopsy. Of the 31 successfully mapped, node positive patients, 5 had false negative (FN) SLNDs (overall FN rate = 16%). Of the 9 successfully mapped patients who had received preoperative chemotherapy and had positive axillary nodes, 3 had FN SLND (FN rate = 33%). The presence of clinically positive lymph nodes before chemotherapy did not predict which patients would have a subsequent FN SLND. T3 tumor size, but not previous excision, was associated significantly with increased FN rate, although the FN rate for previous excision was 11%. No FN SLND occurred with T1/T2 tumors that were not excised previously and had not received preoperative chemotherapy. CONCLUSIONS. Preoperative chemotherapy was associated with an unacceptably high FN rate for SLND. While larger tumor size also was associated with FN SLND, this effect might have been due to preoperative chemotherapy use in these patients. Small sample size precluded determining whether excisional biopsy before mapping increased FN SLND rates independently. (C) 2000 American Cancer Society.

Original languageEnglish (US)
Pages (from-to)2187-2194
Number of pages8
JournalCancer
Volume89
Issue number11
DOIs
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Lymph Node Excision
Breast Neoplasms
Biopsy
Drug Therapy
Axilla
Neoplasms
cyhalothrin
Sentinel Lymph Node
Technetium
Colloids
Eosine Yellowish-(YS)
Sample Size
Coloring Agents
Lymph Nodes

Keywords

  • Axillary lymph nodes
  • Breast carcinoma
  • Excisional biopsy
  • False negative sentinel lymph node
  • Lymphatic mapping
  • Neoadjuvant chemotherapy
  • Preoperative chemotherapy
  • Sentinel lymph node dissection
  • Tumor size

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nason, K. S., Anderson, B. O., Byrd, D. R., Dunnwald, L. K., Eary, J. F., Mankoff, D. A., ... Moe, R. E. (2000). Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer, 89(11), 2187-2194. https://doi.org/10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#

Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. / Nason, Katie S.; Anderson, Benjamin O.; Byrd, David R.; Dunnwald, Lisa K.; Eary, Janet F.; Mankoff, David A.; Livingston, Robert B; Schmidt, Rodney A.; Jewell, Kim D.; Yeung, Raymond S.; Moe, Roger E.

In: Cancer, Vol. 89, No. 11, 01.12.2000, p. 2187-2194.

Research output: Contribution to journalArticle

Nason, KS, Anderson, BO, Byrd, DR, Dunnwald, LK, Eary, JF, Mankoff, DA, Livingston, RB, Schmidt, RA, Jewell, KD, Yeung, RS & Moe, RE 2000, 'Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma', Cancer, vol. 89, no. 11, pp. 2187-2194. https://doi.org/10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#
Nason, Katie S. ; Anderson, Benjamin O. ; Byrd, David R. ; Dunnwald, Lisa K. ; Eary, Janet F. ; Mankoff, David A. ; Livingston, Robert B ; Schmidt, Rodney A. ; Jewell, Kim D. ; Yeung, Raymond S. ; Moe, Roger E. / Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. In: Cancer. 2000 ; Vol. 89, No. 11. pp. 2187-2194.
@article{15ae976c37014469a1a968a4d053f64b,
title = "Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma",
abstract = "BACKGROUND. Sentinel lymph node dissection (SLND) has been a promising new technique in breast carcinoma staging, but could be unreliable in certain patient subsets. The current study assessed whether age, preoperative chemotherapy, tumor size, and/or previous excisional biopsy influenced the identification of sentinel nodes (SLNs) or the reliability of a node-negative SLND in predicting a node negative axilla. METHODS. Eighty-two patients who had clinically negative axillae underwent SLND followed by Level I/II axillary lymph node dissection (ALND). SLNDs were performed using both technetium-99m (Tc-99m) labeled colloid and isosulfan blue dye. SLNs were analyzed by hematoxlyin and eosin and immunocytochemical techniques. RESULTS. SLNs were successfully identified in 80{\%} of patients. Mapping success was decreased among postmenopausal women but was not influenced by preoperative chemotherapy, large tumor size, or previous excisional biopsy. Of the 31 successfully mapped, node positive patients, 5 had false negative (FN) SLNDs (overall FN rate = 16{\%}). Of the 9 successfully mapped patients who had received preoperative chemotherapy and had positive axillary nodes, 3 had FN SLND (FN rate = 33{\%}). The presence of clinically positive lymph nodes before chemotherapy did not predict which patients would have a subsequent FN SLND. T3 tumor size, but not previous excision, was associated significantly with increased FN rate, although the FN rate for previous excision was 11{\%}. No FN SLND occurred with T1/T2 tumors that were not excised previously and had not received preoperative chemotherapy. CONCLUSIONS. Preoperative chemotherapy was associated with an unacceptably high FN rate for SLND. While larger tumor size also was associated with FN SLND, this effect might have been due to preoperative chemotherapy use in these patients. Small sample size precluded determining whether excisional biopsy before mapping increased FN SLND rates independently. (C) 2000 American Cancer Society.",
keywords = "Axillary lymph nodes, Breast carcinoma, Excisional biopsy, False negative sentinel lymph node, Lymphatic mapping, Neoadjuvant chemotherapy, Preoperative chemotherapy, Sentinel lymph node dissection, Tumor size",
author = "Nason, {Katie S.} and Anderson, {Benjamin O.} and Byrd, {David R.} and Dunnwald, {Lisa K.} and Eary, {Janet F.} and Mankoff, {David A.} and Livingston, {Robert B} and Schmidt, {Rodney A.} and Jewell, {Kim D.} and Yeung, {Raymond S.} and Moe, {Roger E.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#",
language = "English (US)",
volume = "89",
pages = "2187--2194",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma

AU - Nason, Katie S.

AU - Anderson, Benjamin O.

AU - Byrd, David R.

AU - Dunnwald, Lisa K.

AU - Eary, Janet F.

AU - Mankoff, David A.

AU - Livingston, Robert B

AU - Schmidt, Rodney A.

AU - Jewell, Kim D.

AU - Yeung, Raymond S.

AU - Moe, Roger E.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - BACKGROUND. Sentinel lymph node dissection (SLND) has been a promising new technique in breast carcinoma staging, but could be unreliable in certain patient subsets. The current study assessed whether age, preoperative chemotherapy, tumor size, and/or previous excisional biopsy influenced the identification of sentinel nodes (SLNs) or the reliability of a node-negative SLND in predicting a node negative axilla. METHODS. Eighty-two patients who had clinically negative axillae underwent SLND followed by Level I/II axillary lymph node dissection (ALND). SLNDs were performed using both technetium-99m (Tc-99m) labeled colloid and isosulfan blue dye. SLNs were analyzed by hematoxlyin and eosin and immunocytochemical techniques. RESULTS. SLNs were successfully identified in 80% of patients. Mapping success was decreased among postmenopausal women but was not influenced by preoperative chemotherapy, large tumor size, or previous excisional biopsy. Of the 31 successfully mapped, node positive patients, 5 had false negative (FN) SLNDs (overall FN rate = 16%). Of the 9 successfully mapped patients who had received preoperative chemotherapy and had positive axillary nodes, 3 had FN SLND (FN rate = 33%). The presence of clinically positive lymph nodes before chemotherapy did not predict which patients would have a subsequent FN SLND. T3 tumor size, but not previous excision, was associated significantly with increased FN rate, although the FN rate for previous excision was 11%. No FN SLND occurred with T1/T2 tumors that were not excised previously and had not received preoperative chemotherapy. CONCLUSIONS. Preoperative chemotherapy was associated with an unacceptably high FN rate for SLND. While larger tumor size also was associated with FN SLND, this effect might have been due to preoperative chemotherapy use in these patients. Small sample size precluded determining whether excisional biopsy before mapping increased FN SLND rates independently. (C) 2000 American Cancer Society.

AB - BACKGROUND. Sentinel lymph node dissection (SLND) has been a promising new technique in breast carcinoma staging, but could be unreliable in certain patient subsets. The current study assessed whether age, preoperative chemotherapy, tumor size, and/or previous excisional biopsy influenced the identification of sentinel nodes (SLNs) or the reliability of a node-negative SLND in predicting a node negative axilla. METHODS. Eighty-two patients who had clinically negative axillae underwent SLND followed by Level I/II axillary lymph node dissection (ALND). SLNDs were performed using both technetium-99m (Tc-99m) labeled colloid and isosulfan blue dye. SLNs were analyzed by hematoxlyin and eosin and immunocytochemical techniques. RESULTS. SLNs were successfully identified in 80% of patients. Mapping success was decreased among postmenopausal women but was not influenced by preoperative chemotherapy, large tumor size, or previous excisional biopsy. Of the 31 successfully mapped, node positive patients, 5 had false negative (FN) SLNDs (overall FN rate = 16%). Of the 9 successfully mapped patients who had received preoperative chemotherapy and had positive axillary nodes, 3 had FN SLND (FN rate = 33%). The presence of clinically positive lymph nodes before chemotherapy did not predict which patients would have a subsequent FN SLND. T3 tumor size, but not previous excision, was associated significantly with increased FN rate, although the FN rate for previous excision was 11%. No FN SLND occurred with T1/T2 tumors that were not excised previously and had not received preoperative chemotherapy. CONCLUSIONS. Preoperative chemotherapy was associated with an unacceptably high FN rate for SLND. While larger tumor size also was associated with FN SLND, this effect might have been due to preoperative chemotherapy use in these patients. Small sample size precluded determining whether excisional biopsy before mapping increased FN SLND rates independently. (C) 2000 American Cancer Society.

KW - Axillary lymph nodes

KW - Breast carcinoma

KW - Excisional biopsy

KW - False negative sentinel lymph node

KW - Lymphatic mapping

KW - Neoadjuvant chemotherapy

KW - Preoperative chemotherapy

KW - Sentinel lymph node dissection

KW - Tumor size

UR - http://www.scopus.com/inward/record.url?scp=0034547964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034547964&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#

DO - 10.1002/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#

M3 - Article

VL - 89

SP - 2187

EP - 2194

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -